Zacks Investment Research downgraded shares of Advanz Pharma (OTCMKTS:CXRXF) from a hold rating to a sell rating in a research report sent to investors on Monday morning, reports.

According to Zacks, “Advanz Pharma Corp. is a specialty pharmaceutical company. It operates primarily in Bridgetown, Barbados; London, England and Mumbai, through its subsidiaries. Advanz Pharma Corp., formerly known as Concordia International Corp., is based in LONDON, UNITED KINGDOM. “

Separately, ValuEngine upgraded shares of Advanz Pharma from a buy rating to a strong-buy rating in a research report on Wednesday, September 4th.

Advanz Pharma stock opened at $13.77 on Monday. The company has a current ratio of 2.33, a quick ratio of 1.98 and a debt-to-equity ratio of 9.26. Advanz Pharma has a 1 year low of $9.32 and a 1 year high of $34.95. The company has a market cap of $769.96 million, a PE ratio of 1.17 and a beta of 0.53. The company’s 50-day moving average is $12.01 and its two-hundred day moving average is $14.98.

Advanz Pharma (OTCMKTS:CXRXF) last released its earnings results on Wednesday, August 7th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.03. Advanz Pharma had a net margin of 322.43% and a negative return on equity of 60.90%. The company had revenue of $131.08 million for the quarter, compared to the consensus estimate of $127.00 million. Research analysts forecast that Advanz Pharma will post -2.09 EPS for the current year.

About Advanz Pharma

ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.

Read More: How to calculate compound interest

Get a free copy of the Zacks research report on Advanz Pharma (CXRXF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Advanz Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanz Pharma and related companies with's FREE daily email newsletter.